Onconetix, Inc. Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions
Onconetix, Inc. (ONCO) reported Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions of $61.41 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Notes › Transfers and Servicing of Financial Assets
us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions · last filed 2023-03-09
- Onconetix, Inc. asset at fair value, changes in fair value resulting from changes in assumptions for fiscal 2022 was $61.41K.
| Period end | Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions 12 month |
|---|---|
| 2022-12-31 | $61.41K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |